DK1685243T3 - Immortaliserede fuglecellelinjer til virusproduktion - Google Patents

Immortaliserede fuglecellelinjer til virusproduktion

Info

Publication number
DK1685243T3
DK1685243T3 DK04798154T DK04798154T DK1685243T3 DK 1685243 T3 DK1685243 T3 DK 1685243T3 DK 04798154 T DK04798154 T DK 04798154T DK 04798154 T DK04798154 T DK 04798154T DK 1685243 T3 DK1685243 T3 DK 1685243T3
Authority
DK
Denmark
Prior art keywords
cell lines
immortalized
virus production
bird cell
production
Prior art date
Application number
DK04798154T
Other languages
English (en)
Inventor
Volker Sandig
Ingo Jordan
Original Assignee
Probiogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34400514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1685243(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Probiogen Ag filed Critical Probiogen Ag
Application granted granted Critical
Publication of DK1685243T3 publication Critical patent/DK1685243T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10251—Methods of production or purification of viral material
    • C12N2710/10252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Manufacturing & Machinery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK04798154T 2003-11-03 2004-11-03 Immortaliserede fuglecellelinjer til virusproduktion DK1685243T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03025158A EP1528101A1 (en) 2003-11-03 2003-11-03 Immortalized avian cell lines for virus production
PCT/EP2004/052789 WO2005042728A2 (en) 2003-11-03 2004-11-03 Immortalized avian cell lines for virus production

Publications (1)

Publication Number Publication Date
DK1685243T3 true DK1685243T3 (da) 2008-10-20

Family

ID=34400514

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08101999.4T DK1939281T4 (da) 2003-11-03 2004-11-03 Immortaliserede andecellelinjer til virusproduktion
DK04798154T DK1685243T3 (da) 2003-11-03 2004-11-03 Immortaliserede fuglecellelinjer til virusproduktion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08101999.4T DK1939281T4 (da) 2003-11-03 2004-11-03 Immortaliserede andecellelinjer til virusproduktion

Country Status (18)

Country Link
US (2) US8940534B2 (da)
EP (4) EP1528101A1 (da)
JP (1) JP4658953B2 (da)
KR (1) KR101027755B1 (da)
CN (1) CN1934243B (da)
AT (2) ATE398672T1 (da)
AU (1) AU2004285089B2 (da)
BR (1) BRPI0415622B8 (da)
CA (1) CA2544462C (da)
CY (1) CY1110272T1 (da)
DE (2) DE602004014526D1 (da)
DK (2) DK1939281T4 (da)
ES (1) ES2309578T3 (da)
PL (1) PL1685243T3 (da)
PT (1) PT1685243E (da)
RU (1) RU2359999C2 (da)
SI (1) SI1685243T1 (da)
WO (1) WO2005042728A2 (da)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004257939B2 (en) * 2003-07-22 2008-06-05 Valneva Production of poxviruses with adherent or non adherent avian cell lines
RS51721B (en) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Reduction of potential iatrogenic risks associated with influenza vaccines
AU2006310171B2 (en) 2005-11-01 2011-02-17 Seqirus UK Limited Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
AU2006310337B9 (en) 2005-11-04 2013-11-28 Novartis Ag Adjuvanted influenza vaccines including cytokine-inducing agents
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP1951299B1 (en) 2005-11-04 2012-01-04 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
CA2628158C (en) 2005-11-04 2015-12-15 Novartis Vaccines And Diagnostics S.R.L. Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
NZ567978A (en) 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP1783210A1 (en) 2005-11-08 2007-05-09 ProBioGen AG Productivity augmenting protein factors, novel cell lines and uses thereof
PL1976559T6 (pl) 2006-01-27 2020-08-10 Novartis Influenza Vaccines Marburg Gmbh Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA2663196A1 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
EP1985305A1 (en) * 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
SI2185191T1 (sl) 2007-06-27 2012-12-31 Novartis Ag Cepiva proti influenci z majhnimi dodatki
CN101688182A (zh) * 2007-07-03 2010-03-31 特兰斯吉恩股份有限公司 永生化禽细胞系
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2008339631B2 (en) 2007-12-24 2014-07-24 Novartis Ag Assays for adsorbed influenza vaccines
KR101445433B1 (ko) * 2008-02-25 2014-09-26 백스터 인터내셔널 인코포레이티드 연속 세포주 제조 방법
US8679839B2 (en) * 2008-03-04 2014-03-25 Probiogen Ag Cell line from rousettus as host cell for pathogen amplification
EP2098590A1 (en) 2008-03-04 2009-09-09 ProBioGen AG Cell line from Rousettus as host cell for pathogen amplification
EP2268309B1 (en) 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
WO2009156155A1 (en) * 2008-06-25 2009-12-30 Probiogen Ag Cell line for propagation of highly attenuated alphaviruses
EP2199385A1 (en) 2008-12-16 2010-06-23 ProBioGen AG Specific and persistent activation of heat shock response in cell lines using a viral factor
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
US20110293660A1 (en) 2009-02-06 2011-12-01 Bruno Rene Andre Novel method
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
CN102438651A (zh) 2009-02-10 2012-05-02 诺华有限公司 用于大流行相关毒株的流感疫苗方案
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
EP2424565A1 (en) 2009-04-27 2012-03-07 Novartis AG Adjuvanted vaccines for protecting against influenza
HRP20220756T1 (hr) 2009-07-15 2022-09-02 Glaxosmithkline Biologicals S.A. Proteinski pripravci rsv f i postupci za izradu istih
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
WO2011040527A1 (ja) * 2009-09-30 2011-04-07 国立大学法人帯広畜産大学 α-ガラクトースエピトープを発現するトランスジェニック鳥類、ウイルス及びワクチン
EP2531592A1 (en) 2010-02-04 2012-12-12 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
CA2792469A1 (en) 2010-03-08 2011-09-15 Novartis Ag Methods of testing for intracellular pathogens
WO2011127316A1 (en) 2010-04-07 2011-10-13 Novartis Ag Method for generating a parvovirus b19 virus-like particle
WO2011139717A1 (en) 2010-04-26 2011-11-10 Novartis Ag Improved production of virus replicon particles in packaging cells
US20130039943A1 (en) 2010-05-03 2013-02-14 Bruno Rene Andre Novel method
US9426989B2 (en) 2010-05-06 2016-08-30 Novartis Ag Organic peroxide compounds for microorganism inactivation
AU2011254204B2 (en) 2010-05-21 2015-08-20 Seqirus UK Limited Influenza virus reassortment method
BR112012030616A2 (pt) 2010-06-01 2017-03-01 Novartis Ag concentração de antígenos de vacina com liofilização.
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
US20130171185A1 (en) 2010-07-06 2013-07-04 Ethan Settembre Norovirus derived immunogenic compositions and methods
WO2012023044A1 (en) 2010-08-20 2012-02-23 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
TR201903651T4 (tr) 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
WO2012059223A1 (en) * 2010-11-02 2012-05-10 Helmholtz-Zentrum für Infektionsforschung GmbH Methods and vectors for cell immortalisation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
TR201908715T4 (tr) 2011-01-26 2019-07-22 Glaxosmithkline Biologicals Sa Rsv immünizasyon rejimi.
PL2707385T3 (pl) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Prefuzyjne antygeny RSV F
EP2724157B1 (en) 2011-06-27 2017-03-08 Valneva Method for screening cells
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
EP2729168A2 (en) 2011-07-06 2014-05-14 Novartis AG Immunogenic compositions and uses thereof
MX2014004214A (es) 2011-10-11 2014-05-07 Novartis Ag Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
EP2766385A2 (en) 2011-10-12 2014-08-20 Novartis AG Cmv antigens and uses thereof
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
US20140248320A1 (en) 2011-10-20 2014-09-04 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
EP2660316A1 (en) 2012-05-02 2013-11-06 Helmholtz-Zentrum für Infektionsforschung GmbH Avian cell line and its use in production of protein
JP2015522580A (ja) 2012-07-06 2015-08-06 ノバルティス アーゲー 免疫学的組成物およびその使用
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
EP2922570A1 (en) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
CN103060376A (zh) * 2012-12-11 2013-04-24 上海实验动物研究中心 一种禽腺病毒转移载体及其制备方法
MX2015008847A (es) 2013-01-10 2015-10-30 Novartis Ag Composiciones inmunogenicas de virus de influenza y usos de las mismas.
US20140255447A1 (en) * 2013-03-05 2014-09-11 Biomune Company Production of avian embryo cells
CA2920934C (en) 2013-08-30 2022-12-06 Glaxosmithkline Biologicals S.A. Large scale production of viruses in cell culture
CN104726409B (zh) * 2013-12-19 2017-12-29 普莱柯生物工程股份有限公司 一种永生化的鸭胚肝细胞系的制备方法和应用
EP3125685A4 (en) * 2014-04-02 2017-11-08 Alexion Pharmaceuticals, Inc. Producing therapeutic proteins
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
WO2016008976A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
PL3227433T3 (pl) 2014-12-04 2019-01-31 Intervet International B.V. Unieśmiertelnione fibroblasty zarodków kurzych
EP3031822A1 (en) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
WO2016096688A1 (en) 2014-12-16 2016-06-23 Glaxosmithkline Biologicals S.A. A method for a large scale virus purification
KR102526616B1 (ko) 2014-12-17 2023-04-27 푼다시온 파라 라 인베스티가시온 메디카 아플리카다 윌슨병 및 기타 병태의 치료에 사용되기 위한 핵산 구조물 및 유전자 치료용 벡터
WO2016097218A1 (en) 2014-12-17 2016-06-23 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
HUE051783T2 (hu) 2015-07-07 2021-03-29 Seqirus Uk Ltd Eljárás immunogén hemagglutinin mennyiségi meghatározására
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
CN107012122A (zh) * 2016-12-12 2017-08-04 江苏省农业科学院 一种永生化鸡胚胎肝细胞系及其制备方法和用途
JP7110203B2 (ja) 2016-12-28 2022-08-01 トランジェーヌ 腫瘍溶解性ウイルスおよび治療用分子
SG11201908280SA (en) 2017-03-30 2019-10-30 Univ Queensland "chimeric molecules and uses thereof"
SG11201912429RA (en) 2017-06-21 2020-01-30 Transgene Sa Personalized vaccine
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
WO2019040994A1 (en) 2017-09-01 2019-03-07 The Australian National University IMMUNOREGULATOR MOLECULES AND USES THEREOF
CA3081436A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
MA50942A (fr) 2017-12-01 2020-10-07 Encoded Therapeutics Inc Protéines de liaison à l'adn modifiées
EP3794127A1 (en) 2018-05-14 2021-03-24 Vivet Therapeutics Gene therapy vectors comprising s/mar sequences
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
CA3106286A1 (en) 2018-07-13 2020-01-16 Valneva Se Method for rescuing and producing a virus in avian cells
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
CN110396496B (zh) * 2018-09-30 2023-06-20 湖北省农业科学院畜牧兽医研究所 一种鸭小肠上皮细胞的培养方法及应用
JP2022508724A (ja) 2018-10-12 2022-01-19 ヴィヴェ テラピューティクス 進行性家族性肝内胆汁鬱滞タイプ３（ｐｆｉｃ３）の治療のためのコドン最適化導入遺伝子
SG11202104634UA (en) 2018-11-07 2021-06-29 Vivet Therapeutics Codon-optimized abcb11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (pfic2)
CN109321516A (zh) * 2018-11-07 2019-02-12 贵州大学 一种鸭原代肝细胞分离及培养方法
TW202039854A (zh) 2018-11-16 2020-11-01 美商編碼製藥公司 治療威爾遜氏病的組合物和方法
US20220017859A1 (en) 2018-11-23 2022-01-20 Valneva Se Food Products Comprising Avian Stem Cells
US20220056481A1 (en) 2018-12-28 2022-02-24 Transgene M2-defective poxvirus
EP3686276A1 (en) * 2019-01-28 2020-07-29 Freie Universität Berlin Production of viruses in continuously growing epithelial cell lines derived from chicken gut
CA3145446A1 (en) 2019-07-02 2021-01-07 Fundacion Para La Investigacion Medica Aplicada Cpla2e inducing agents and uses thereof
AU2020318680A1 (en) 2019-07-21 2022-02-17 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
WO2021099419A1 (en) 2019-11-18 2021-05-27 Seqirus UK Limited Method for producing reassortant influenza viruses
US20210315986A1 (en) 2020-04-13 2021-10-14 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
CA3189238A1 (en) 2020-07-13 2022-01-20 Transgene Treatment of immune depression
TW202214864A (zh) 2020-08-06 2022-04-16 應用醫學研究基金會 用於藉基因療法治療諸如阿茲海默症之Ｔａｕ蛋白病變的病毒顆粒
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
MX2023003994A (es) 2020-10-09 2023-04-24 UCB Biopharma SRL Construcciones de acido nucleico, vectores virales y particulas virales.
EP4267197A1 (en) 2020-12-23 2023-11-01 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
EP4274886A2 (en) 2021-01-10 2023-11-15 Supermeat the Essence of Meat Ltd. Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
JP2024516400A (ja) 2021-04-30 2024-04-15 カリヴィル イムノセラピューティクス， インコーポレイテッド 修飾されたｍｈｃ発現のための腫瘍溶解性ウイルス
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
EP4419650A1 (en) 2021-10-18 2024-08-28 Supermeat the Essence of Meat Ltd. Methods for preparing a food ingredient and compositions produced thereby
KR20240099360A (ko) 2021-10-28 2024-06-28 유씨비 바이오파마 에스알엘 핵산 구축물, 바이러스 벡터 및 바이러스 입자
CN114350601B (zh) * 2021-12-21 2022-12-27 广东省华晟生物技术有限公司 樱桃谷鸭成纤维细胞系及其构建方法与应用
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN114908053A (zh) * 2022-04-24 2022-08-16 上海交通大学 孔雀成纤维永生化细胞系的制备方法及其在病毒扩增中的应用
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
TW202413636A (zh) 2022-08-18 2024-04-01 法商傳斯堅公司 嵌合痘病毒
CN116496992B (zh) * 2023-04-24 2023-12-01 江苏省家禽科学研究所 一种鸡胚成肌永生化细胞及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0833934T4 (da) * 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
KR970010968A (ko) 1995-08-24 1997-03-27 윤원영 오리 배 세포를 이용한 에리스로포이틴의 발현 시스템
US5989805A (en) 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
FR2749022B1 (fr) * 1996-05-23 2001-06-01 Rhone Merieux Cellules aviaires immortelles
US5830723A (en) 1996-08-13 1998-11-03 Regents Of The University Of Minnesota Method for immortalizing chicken cells
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
FR2767335B1 (fr) 1997-08-14 2001-09-28 Ct Nat D Etudes Veterinaires E Adenovirus aviaire celo recombinant comme vecteur vaccinant
DE19955558C2 (de) * 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
CN1139655C (zh) * 2001-08-23 2004-02-25 北京大学人民医院 一种人卵巢癌永生化细胞株及其建立方法
US7473536B2 (en) 2002-08-07 2009-01-06 Bavarian Nordic A/S Isolated avian cell that expresses Vaccinia virus host range genes
DK1434858T4 (da) 2002-09-05 2019-04-01 Bavarian Nordic As Fremgangsmåde til amplifikation af et poxvirus under serumfri betingelser
AU2004257939B2 (en) 2003-07-22 2008-06-05 Valneva Production of poxviruses with adherent or non adherent avian cell lines

Also Published As

Publication number Publication date
ES2309578T3 (es) 2008-12-16
WO2005042728A2 (en) 2005-05-12
ATE398672T1 (de) 2008-07-15
EP1939281A1 (en) 2008-07-02
EP2192173A1 (en) 2010-06-02
JP4658953B2 (ja) 2011-03-23
WO2005042728A3 (en) 2005-07-07
DK1939281T4 (da) 2014-08-25
CY1110272T1 (el) 2015-01-14
BRPI0415622B8 (pt) 2021-05-25
DE602004025996D1 (de) 2010-04-22
US20120288916A1 (en) 2012-11-15
EP1685243A2 (en) 2006-08-02
PT1685243E (pt) 2008-09-24
BRPI0415622A (pt) 2006-12-12
US20080227146A1 (en) 2008-09-18
CA2544462A1 (en) 2005-05-12
BRPI0415622B1 (pt) 2021-01-26
CN1934243A (zh) 2007-03-21
SI1685243T1 (sl) 2008-12-31
AU2004285089A1 (en) 2005-05-12
JP2007510409A (ja) 2007-04-26
EP1685243B1 (en) 2008-06-18
EP1528101A1 (en) 2005-05-04
KR20060123758A (ko) 2006-12-04
RU2359999C2 (ru) 2009-06-27
RU2006119447A (ru) 2007-12-20
ATE460473T1 (de) 2010-03-15
DK1939281T3 (da) 2010-06-14
EP1939281B2 (en) 2014-06-04
DE602004014526D1 (de) 2008-07-31
AU2004285089B2 (en) 2009-07-02
KR101027755B1 (ko) 2011-04-07
CA2544462C (en) 2011-10-25
PL1685243T3 (pl) 2008-12-31
CN1934243B (zh) 2011-07-06
EP1939281B1 (en) 2010-03-10
US8940534B2 (en) 2015-01-27

Similar Documents

Publication Publication Date Title
DK1685243T3 (da) Immortaliserede fuglecellelinjer til virusproduktion
CL2021002739A1 (es) Proteína crispr de prevotella y francisella 1 (cpf1) aislada de acidaminococcus sp. bv3l6; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004)
DE50214416D1 (de) Vermehrung von viren in zellkultur
WO2007048089A3 (en) Multi-plasmid system for the production of influenza virus
ATE547511T1 (de) Nichttumorbildende mdck-zellinie zur vermehrung von viren
CY1119106T1 (el) Αντισωματα εναντι masp-2
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
NO20073737L (no) Hjelp for influensavirus
EA201200217A1 (ru) Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
EA200970996A1 (ru) Стволовые клеточные линии, полученные из эмбрионов утки, для производства вирусных вакцин
EP1697521A4 (en) PLASMID MULTIPLE SYSTEM FOR PRODUCING INFLUENZA VIRUS
WO2007002008A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
BRPI0519705A2 (pt) composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
ATE507242T1 (de) Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
EA201001045A1 (ru) Модифицированный вирус гриппа
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
EA201390856A1 (ru) Инактивация вирусов с применением улучшенного способа растворитель-детергент
WO2005115448A3 (en) Multi plasmid system for the production of influenza virus
CY1121438T1 (el) Μεθοδοι για την παρασκευη υδροπηκτων χρησιμοποιωντας ενζυμα λιπασης
AR024122A1 (es) Metodo para la estabilizacion intensificada de proteinas y produccion de lineas celulares que sirven para la produccion de dichas proteinas estabilizadas
WO2007019532A3 (en) Peptide aptamers that bind to the rep proteins of ssdna viruses
DK1537204T3 (da) Granzym B som HSP70/HSP70-peptidafhængig udløser af programmeret celledød hos tumorceller
DK1383796T3 (da) Neurovirulent stamme af viruset West Nile og anvendelser heraf